Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Birkhead

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reports|June 1, 1985
Mathematical model of remission duration in acute myelogenous leukemiaB G Birkhead
Hematological Oncology|April 1, 1987
Reliability and consistency of bone marrow assessments of complete remission in acute myelogenous leukaemiaB G Birkhead, D Salt, R R Jackson
Antibiotics and Chemotherapy|January 1, 1988
Mathematical models in high-dose chemotherapyR L Souhami, W M Gregory, B G Birkhead
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
A mathematical model of drug resistance applied to treatment for small-cell lung cancerW M Gregory, B G Birkhead, R L Souhami
Cancer Chemotherapy and Pharmacology|January 1, 1987
Towards an assessment of toxicity in the treatment of ovarian cancerL Dones, E Wiltshaw, B G Birkhead, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1986
Evaluating and designing cancer chemotherapy treatment using mathematical modelsB G Birkhead, W M Gregory, M L Slevin, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1987
A mathematical model of the development of drug resistance to cancer chemotherapyB G Birkhead, E M Rankin, S Gallivan, et al.
The Journal of the Operational Research Society|February 10, 1982
Application of Jackson, Aspden Acute Myeloid Leukaemia modelR R Jackson, B G Birkhead, R Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1985
High-dose cyclophosphamide in small-cell carcinoma of the lungR L Souhami, G Finn, W M Gregory, et al.
British Medical Journal (Clinical Research Ed.)|April 24, 1982
Short-term treatment for acute myelogenous leukaemiaR Bell, A Z Rohatiner, M L Slevin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reports|June 1, 1985
Mathematical model of remission duration in acute myelogenous leukemiaB G Birkhead
Hematological Oncology|April 1, 1987
Reliability and consistency of bone marrow assessments of complete remission in acute myelogenous leukaemiaB G Birkhead, D Salt, R R Jackson
Antibiotics and Chemotherapy|January 1, 1988
Mathematical models in high-dose chemotherapyR L Souhami, W M Gregory, B G Birkhead
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
A mathematical model of drug resistance applied to treatment for small-cell lung cancerW M Gregory, B G Birkhead, R L Souhami
Cancer Chemotherapy and Pharmacology|January 1, 1987
Towards an assessment of toxicity in the treatment of ovarian cancerL Dones, E Wiltshaw, B G Birkhead, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1986
Evaluating and designing cancer chemotherapy treatment using mathematical modelsB G Birkhead, W M Gregory, M L Slevin, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1987
A mathematical model of the development of drug resistance to cancer chemotherapyB G Birkhead, E M Rankin, S Gallivan, et al.
The Journal of the Operational Research Society|February 10, 1982
Application of Jackson, Aspden Acute Myeloid Leukaemia modelR R Jackson, B G Birkhead, R Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1985
High-dose cyclophosphamide in small-cell carcinoma of the lungR L Souhami, G Finn, W M Gregory, et al.
British Medical Journal (Clinical Research Ed.)|April 24, 1982
Short-term treatment for acute myelogenous leukaemiaR Bell, A Z Rohatiner, M L Slevin, et al.
Pageof 1